GlassScriptPhysician profile
Hitendra M Rambhia
NPI 1629061155
$10,734.15
in general payments reported to CMS, 2019-2025
39 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $252 · 2021: $2,383 · 2022: $2,060 · 2023: $1,789 · 2024: $1,415 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $659 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.34 |
| Education | $658.85 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,880.35 | 2019-2025 | |
| Janssen Biotech, INC. | $1,007.24 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Genzyme Corporation | $728.48 | 2020-2025 | |
| Pfizer INC. | $704.57 | 2019-2025 | |
| Incyte Corporation | $671.03 | 2019-2025 | Jakafi |
| Eisai INC. | $482.99 | 2021-2025 | |
| Astellas Pharma US INC | $412.69 | 2019-2023 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $408.51 | 2021-2025 | Opdivo, Krazati |
| Amgen INC. | $359.84 | 2021-2023 | Nplate, Xgeva, Lumakras |
| Lilly USA, LLC | $322.84 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $230.03 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $198.95 | 2021-2022 | |
| Puma Biotechnology, INC. | $192.86 | 2023-2025 | Nerlynx |
| Merck Sharp & Dohme LLC | $173.64 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $160.35 | 2019-2025 | Tagrisso, Calquence |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $138.14 | 2022-2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $134.20 | 2024-2025 | Enhertu, Datroway |
| Array Biopharma INC | $133.18 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Karyopharm Therapeutics INC. | $128.15 | 2022-2025 | Xpovio |
| Seagen INC. | $126.67 | 2023-2025 | Tukysa |
| Rigel Pharmaceuticals, INC. | $123.54 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $119.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.13 | 2023-2025 | |
| Dova Pharmaceuticals | $83.24 | 2020-2021 | |
| Mirati Therapeutics, INC. | $82.84 | 2023-2024 | Krazati |
| Exelixis INC. | $81.99 | 2022-2025 | Cabometyx |
| Acrotech Biopharma INC. | $81.84 | 2024-2025 | Beleodaq |
| Pharmaessentia USA Corporation | $71.49 | 2024 | Besremi |
| Glaxosmithkline, LLC. | $63.44 | 2023-2025 | Ojjaara, Shingrix |
| Accord Healthcare, INC. | $55.59 | 2025 | |
| Kite Pharma, INC. | $44.43 | 2023 | Yescarta |
| Azurity Pharmaceuticals, INC. | $43.17 | 2024 | Vivimusta |
| Shield Therapeutics INC | $41.61 | 2023 | Accrufer |
| Global Blood Therapeutics, INC. | $37.12 | 2020-2021 | |
| Taiho Oncology, INC. | $36.68 | 2022 | |
| Clovis Oncology, INC. | $20.83 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.19 | 2023 | Ultomiris |
| Verity Pharmaceuticals INC. | $16.77 | 2022 | |
| Gilead Sciences, INC. | $15.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hitendra Rambhia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.